Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency

NCT01916993 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT01916993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01916993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency
Lead sponsor
Neurocrine Biosciences
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
December 31, 2013
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

safety, tolerability, and pk of nbi-98854 in hepatically impaired subjects